Maximusnd/iStock via Getty Images Key takeaways 1 The fund underperformed its benchmark for the quarter Underperformance was primarily driven by stock selection in the health care, industrials and financials sectors. Stronger stock selection in the information technology and real estate sectors partially offset these results. 2 Portfolio activity There was no significant change to the fund's overa...
Maximusnd/iStock via Getty Images Key takeaways 1 The fund underperformed its benchmark for the quarter Underperformance was primarily driven by stock selection in the health care, industrials and financials sectors. Stronger stock selection in the information technology and real estate sectors partially offset these results. 2 Portfolio activity There was no significant change to the fund's overall positioning during the quarter as we sought to keep most sector, factor and other macro-related exposures similar to the Russell 2000 Index. 3 US small-caps outperformed Equities faced increased volatility amid geopolitical tension, higher energy prices and artificial intelligence-related concerns. US small-caps outperformed the broader market as leadership rotated away from mega cap stocks. The Russell 2000 Index returned 0.89%. Manager perspective and outlook • US financial markets had a volatile first quarter, marked by shifting monetary policy expectations, geopolitical instability and uneven economic data. • Equities started 2026 with momentum as earnings remained solid and market leadership broadened beyond mega cap growth stocks. Volatility rose later in the quarter due to the Iran conflict, higher energy prices and concerns about AI disruption. • Economic growth remained positive but showed signs of softening, as job gains slowed, unemployment edged higher and inflation stayed above the US Federal Reserve's (Fed) 2% target. • Following three interest rate cuts in late 2025, the Fed left the federal funds rate unchanged during the quarter, signaling a more cautious stance with rates staying "higher for longer" in response to persistent inflation and a cooling labor market. • Major equity indexes declined amid heightened volatility, with the S&P 500 Index returning -4.33%. Energy stocks outperformed on rising oil prices, while financials, consumer discretionary and IT lagged. Small-caps outperformed the broader market, with the Russell 2000 Index returning 0.89%, l...
Corn futures were down 9 to 15 cents in the front months on Thursday, falling with the rest of the grain complex as very few details were announced out of the Trump/Xi meeting. May futures expired today. The CmdtyView national average Cash Corn price was down 13 cents to $4.27....
Corn futures were down 9 to 15 cents in the front months on Thursday, falling with the rest of the grain complex as very few details were announced out of the Trump/Xi meeting. May futures expired today. The CmdtyView national average Cash Corn price was down 13 cents to $4.27....
Lean hog futures saw losses of 45 cents to $1.35 in the front months on Thursday. USDA’s national base hog price was reported at $93.32 on Thursday afternoon, down $2.19 from the day prior. The CME Lean Hog Index was back up 26 cents on May 12 at $90.74. Export...
Lean hog futures saw losses of 45 cents to $1.35 in the front months on Thursday. USDA’s national base hog price was reported at $93.32 on Thursday afternoon, down $2.19 from the day prior. The CME Lean Hog Index was back up 26 cents on May 12 at $90.74. Export...
Live cattle futures retreated from early gains on Thursday with contracts down 32 to 72 cents at the close. Cash trade has seen some $260 sales in the South this week with, with northern trade at $408-415 dressed and $265 live. Feeder cattle futures posted $1.20 to $2.92 losses on...
Live cattle futures retreated from early gains on Thursday with contracts down 32 to 72 cents at the close. Cash trade has seen some $260 sales in the South this week with, with northern trade at $408-415 dressed and $265 live. Feeder cattle futures posted $1.20 to $2.92 losses on...
In this article .HSI .N225 .AXJO @DJ.1 @SP.1 @ND.1 .DJI .SPX .IXIC Follow your favorite stocks CREATE FREE ACCOUNT China's President Xi Jinping (R) and US President Donald Trump visit the Temple of Heaven in Beijing on May 14, 2026. Xi warned Trump that the issue of Taiwan could push their two countries into "conflict" if mishandled, a stark opening salvo as a superpower summit set to tackle numer...
In this article .HSI .N225 .AXJO @DJ.1 @SP.1 @ND.1 .DJI .SPX .IXIC Follow your favorite stocks CREATE FREE ACCOUNT China's President Xi Jinping (R) and US President Donald Trump visit the Temple of Heaven in Beijing on May 14, 2026. Xi warned Trump that the issue of Taiwan could push their two countries into "conflict" if mishandled, a stark opening salvo as a superpower summit set to tackle numerous thorny issues began in Beijing on May 14. (Photo by Brendan SMIALOWSKI / POOL / AFP via Getty Images) Brendan Smialowski | Afp | Getty Images South Korea's benchmark Kospi notched a fresh record high on Friday, leading gains in Asia-Pacific markets as investors tracked the second day of high-stakes talks between U.S. President Donald Trump and Chinese President Xi Jinping . The index rose more than 0.6% to more than 8,000, while the small-cap Kosdaq was down 0.4%. Japan's Nikkei 225 added 0.89% and the Topix jumped 1.18%. In Australia, the S&P/ASX 200 gained 0.42%. Hong Kong's Hang Seng index futures were at 26,341, slightly below the index's last close of 26,389.04. The Kospi topped 7,000 for the first time on May 5 after index heavyweight Samsung Electronics reached a record high to cross $1 trillion in market capitalization. The record-breaking streak comes amid concerns of concentration risks , particularly in artificial intelligence stocks. Samsung Electronics and SK Hynix together made up a record 42.2% of the Kospi in May, according to Manulife Investment Management. The gains in South Korea's market also reflected investor optimism that the Trump-Xi talks could ease tensions around trade and technology exports, particularly for chipmakers and AI-related stocks. Trump arrived in Beijing on Wednesday for the closely watched summit, joined by a delegation of American business leaders, including Tesla CEO Elon Musk and Nvidia chief Jensen Huang. Xi warned Trump on Thursday that Washington and Beijing could face "clashes and even conflicts" if the sensitive issue of ...
Yarphoto/iStock via Getty Images Compass Pathways’ ( CMPS ) stock has performed well in 2026, driven by a series of positive developments. In particular, Phase III trial data was solid, leading investors to reassess the probability of commercial success. More recently, psychedelics have also received presidential backing, providing further momentum. While a broad range of outcomes remain possible ...
Yarphoto/iStock via Getty Images Compass Pathways’ ( CMPS ) stock has performed well in 2026, driven by a series of positive developments. In particular, Phase III trial data was solid, leading investors to reassess the probability of commercial success. More recently, psychedelics have also received presidential backing, providing further momentum. While a broad range of outcomes remain possible at this point in time, I would argue that Compass Pathways is still undervalued, assuming even fairly modest penetration of its target market. The bull case would see psychedelics broadly adopted for a range of mental health conditions and increasingly used as a frontline option when patients fail to respond to medications like SSRIs. This would likely see Compass generate extremely strong returns. Success will be heavily dependent on Phase III trial results for alternative psychedelic therapies and how the various TRD treatment options are viewed by healthcare professionals, though. Market There are a broad range of treatment options available to people suffering from MDD, and yet there remains a large gap in the market that stems from the fact that many people do not respond to existing treatments. There are around 4 million MDD patients in the US who have treatment-resistant depression, which is typically defined as having failed to respond to 2 or more antidepressants. First-line treatment for MDD is pharmacotherapy/psychotherapy, followed by neurostimulation if there is a poor response or side effects. Frontline treatment options offer limited relief for a meaningful proportion of patients, though. For example, studies suggest only around 37% of patients achieve remission with the first treatment option, and remission rates decline with alternative treatment options. While there are over 55 medicines approved for MDD, there are only 2 approved for TRD (esketamine and olanzapine (antipsychotic) & fluoxetine (antidepressant) in combination). This is particularly problema...
(RTTNews) - The Taiwan stock market bounced higher again on Thursday, one day after ending the two-day winning streak in which it had gained almost 300 points or 0.7 percent. The Taiwan Stock Exchange now sits just above the 41,750-point plateau and it may add to its winnings on
(RTTNews) - The Taiwan stock market bounced higher again on Thursday, one day after ending the two-day winning streak in which it had gained almost 300 points or 0.7 percent. The Taiwan Stock Exchange now sits just above the 41,750-point plateau and it may add to its winnings on
Soybeans posted 20 to 40 ¾ cent losses across most contracts on Thursday. The cmdtyView national average Cash Bean price was down 36 cents at $11.28. Soymeal futures were back down $3.90 to $6, with Soy Oil futures falling 44 to 83 points. May futures expired today. A meeting between...
Soybeans posted 20 to 40 ¾ cent losses across most contracts on Thursday. The cmdtyView national average Cash Bean price was down 36 cents at $11.28. Soymeal futures were back down $3.90 to $6, with Soy Oil futures falling 44 to 83 points. May futures expired today. A meeting between...